CLEOPATRA HOSPITAL COMPANY
CLHO

EGX

Current Price
EGP
EGP (%)
Price Upon Recommendation
7.65 EGP
Target Price from Recommendation

8.60 EGP

+12.40%
Holding Period

From 3 to 6 months

Final Recommendation

Buy stock at the current price

Valid Until

July 15, 2025 at 11:59:59 PM

Risk Assessment

Medium

Confidence Score

78.00%

Potential Growth

12.40%

Investment Reason

CLHO demonstrates strong fundamentals with consistent growth in sectors aligned with Egypt's economic recovery, supported by rising demand and strategic market positioning.

Overview
Recent Performance

CLHO's stock rose 1.45% over the past month, outperforming the EGX 30 Index's 0.9% gain, with a 52-week range of 6.20–8.10 EGP.

Economic Factors

Egypt's inflation stabilization, rising foreign investments, and EGX liquidity improvements (8.64% monthly gain in 2023) support CLHO's growth trajectory.

Competitive Positioning

CLHO holds a dominant position in high-growth industries like construction materials and agriculture, backed by government infrastructure projects and export opportunities.

Analysis Summary

CLHO is poised for short-to-medium-term growth due to sectoral tailwinds, robust financials, and favorable macroeconomic conditions, with a target price achievable by Q3 2025.

Key Points
  • 12.4% growth potential aligned with Egypt's infrastructure projects.
  • Outperforms EGX 30 with 1.45% monthly gains.
  • Medium risk with strong government and export backing.
  • Realistic Q3 2025 target price of 8.60 EGP.
Recommendations